Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe.

Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P; ADVANCE Working Group..

Haemophilia. 2016 Mar;22(2):248-255. doi: 10.1111/hae.12847.

PMID:
27880029
2.

The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII.

Pabinger-Fasching I.

Thromb Res. 2016 May;141 Suppl 3:S2-4. doi: 10.1016/S0049-3848(16)30414-5. Review.

3.

Pioneering therapeutic proteins in hemophilia care through innovative technologies.

Pabinger-Fasching I, Négrier C.

Thromb Res. 2016 May;141 Suppl 3:S1. doi: 10.1016/S0049-3848(16)30413-3. No abstract available.

4.

Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.

Lalezari S, Coppola A, Lin J, Enriquez MM, Tseneklidou-Stoeter D, Powell J, Ingerslev J; LIPLONG Investigators..

Haemophilia. 2014 May;20(3):354-61.

PMID:
24847524
5.

[Prevention of venous thromboembolism in musculoskeletal surgery].

Pabinger-Fasching I, Eichinger-Hasenauer S, Grohs J, Hochreiter J, Kastner N, Korninger HC, Kozek-Langenecker S, Marlovits S, Niessner H, Rachbauer F, Ritschl P, Wurnig C, Windhager R.

Wien Klin Wochenschr. 2014 May;126(9-10):298-310. doi: 10.1007/s00508-014-0509-5. German.

PMID:
24825594
6.

Oral apixaban for the treatment of acute venous thromboembolism.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators..

N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507.

7.

[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts].

Watzke H, Metzler H, Weltermann A, Marschang P, Brodmann M, Lang W, Pabinger-Fasching I, Mahla E, Kozek-Langenecker S, Guschmann M, Huber K.

Wien Klin Wochenschr. 2013 Jul;125(13-14):412-20. German.

PMID:
23797530
8.

Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation.

Freynhofer MK, Draxler DF, Gruber SC, Bruno V, Höchtl T, Fellner B, Jakl-Kotauschek G, Wojta J, Pabinger-Fasching I, Huber K, Ay C.

J Thromb Haemost. 2013 Jun;11(6):1069-77. doi: 10.1111/jth.12213.

9.

Innovations in coagulation: improved options for treatment of hemophilia A and B.

Pabinger-Fasching I, Pipe S.

Thromb Res. 2013 Mar;131 Suppl 2:S1. doi: 10.1016/S0049-3848(13)00051-0. No abstract available.

PMID:
23537720
10.

Apixaban for extended treatment of venous thromboembolism.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; PLIFY-EXT Investigators..

N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541.

11.

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.

Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group..

Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512.

12.

Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.

Powell J, Martinowitz U, Windyga J, Di Minno G, Hellmann A, Pabinger I, Maas Enriquez M, Schwartz L, Ingerslev J; LipLong Study Investigators..

Thromb Haemost. 2012 Nov;108(5):913-22. doi: 10.1160/TH12-03-0188.

PMID:
23014711
13.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M.

Blood. 2012 Sep 20;120(12):2405-11.

14.

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.

Michel M, te Boekhorst PA, Janssens A, Pabinger-Fasching I, Sanz MA, Nie K, Kreuzbauer G.

Hematology. 2011 Sep;16(5):274-7. doi: 10.1179/102453311X13025568942005.

15.

[Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].

Auerswald G, Muntean W, Kemkes-Matthes B, Klamroth R, Krause M, Kurnik K, Oldenburg J, Pabinger-Fasching I, Schramm W, Zimmermann R, Zotz RB.

Hamostaseologie. 2009 May;29(2):197-203. German.

PMID:
19404511
16.

Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.

Pabinger-Fasching I.

Thromb Res. 2008;122 Suppl 2:S19-22. doi: 10.1016/S0049-3848(08)70005-7. Review.

PMID:
18549908
17.

The course of anticardiolipin antibody levels under immunoadsorption therapy.

Hauser AC, Hauser L, Pabinger-Fasching I, Quehenberger P, Derfler K, Hörl WH.

Am J Kidney Dis. 2005 Sep;46(3):446-54.

PMID:
16129206
18.

Fibrinolytic therapy with rt-PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome.

Hauser AC, Brichta A, Pabinger-Fasching I, Jäger U.

Ann Hematol. 2003 May;82(5):299-302.

PMID:
12707719
19.

A patient with sudden abdominal pain 10 years after successful renal transplantation.

Hauser AC, Pabinger-Fasching I, Quehenberger P, Kettenbach J, Hörl WH.

Nephrol Dial Transplant. 2003 May;18(5):1021-5. No abstract available.

PMID:
12686684
20.

Evaluation of a highly specific functional test for the detection of factor V Leiden.

Quenhenberger P, Handler S, Mannhalter C, Pabinger-Fasching I, Speiser W.

Int J Clin Lab Res. 2000;30(3):113-7.

PMID:
11196068

Supplemental Content

Loading ...
Support Center